ABVC · Abvc Biopharma, Inc. · Executive Compensation
$0.97
-0.01 (-1.02%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“For the six months ended June 30, 2026, the Company reported net loss of $2,500,418. As of June 30, 2026, the Company's working capital deficit was $5,282,776. In addition, the Company had net cash outflows of $1,138,656 from operating activities for the six months ended June 30, 2026. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$29.29M
Shares
26.65M
Volume · Oct 6
92.4K
Avg daily vol (3M)
128.28K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Leeds Chow | Chief Financial Officer | Resigned | 2025-03-07 |
| Uttam Patil | Interim Chief Financial Officer | Appointed | 2024-07-23 |
| Uttam Yashwant Patil | Chief Executive Officer | Appointed | 2023-06-23 |
| Howard Doong | Chief Executive Officer | Resigned | 2023-06-23 |
| Richard King | Chief Scientific Officer ("CSO") | Resigned | 2023-06-15 |
| Leeds Chow | Chief Financial Officer and Principal Accounting Officer | Appointed | 2022-09-09 |
| Yu-Min (Francis) Chung | director | Appointed | 2022-07-14 |
| Kuang-Tseng Chen | director | Resigned | 2022-07-14 |